Tag Archives: Glen Weiss

clinical research advantage - vaccines

CTCA Opening New Set of Clinical Trials

Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western) in Goodyear announced it will launch 12 additional industry-sponsored clinical trials from now through December 2014. New trials will include both Phases I and II studies seeking to provide treatment options for multiple cancer types, including pancreatic, lung, prostate, colorectal and bladder.

“These research studies further our mission at CTCA® to improve overall cancer care, providing additional, innovative treatment options for our patients,” said Glen Weiss, Director of Clinical Research and Medical Oncologist, CTCA at Western.

The additional 12 trials will bring the number of open trials to 54 from 42. Patient enrollment in treatment trials has increased by more than 550 percent since the clinical research program’s inception in 2012, with Western’s clinical research team treating more than 100 patients on clinical trials involving novel treatments. This year Western exceeds the national average for adult patients participating on research studies by more than 300 percent. The breadth of research includes participation from the majority of Western’s medical oncologists who are committed to opening trials as quickly as possible.

“We truly value a patient’s immediate need for treatment options and do our best to ensure trials are fully operational in a matter of weeks versus months,” added Weiss.

For more information on the CTCA clinical trials program as well as trials currently open, visit http://www.cancercenter.com/clinical-trials/.

10258873_934794563202520_1916243681706580952_o

Az Business honors healthcare leaders

Each year, Az Business magazine hosts the Healthcare Leadership Awards to honor the women, men and institutions that bring excellence and innovation to Arizona’s healthcare system. Here are the winners and finalists who were chosen by a panel of industry experts and were recognized at the 2014 Healthcare Leadership Awards on Thursday, April 10 at the Ritz Carlton in Phoenix. See photos from the event here or on our Facebook page.

BIOSCIENCE COMPANY
Winner: Translational Genomics Research Institute (TGen)
TGen has made great strides in the field if genomics medicine. TGen researchers work to help physicians prescribe drugs that are designed more intelligently, work more effectively and have fewer toxic side effects. They have received numerous grants to support research into brain cancer and brain injuries, advanced cancers, Parkinson’s, rare childhood disorders, and more.

Finalists:
Barrow at PCH
Sonora Quest

COMMUNITY OUTREACH/EDUCATION
Winner: Barbara Kavanagh, Arizona Myeloma Network
Kavanagh’s mission is to change the lack of information and support resources for myeloma cancer by forming the Arizona Myeloma Network and the Living with Myeloma Conference, which has grown to 300 people. She also introduced the Pat and Bill Hite Cancer Caregivers Education and Support Program for caregivers to receive support and answers.

Finalists:
Catherine Ivy, Ben and Catherine Ivy Foundation
Kathleen Goeppinger, Ph.D., Midwestern University

HEALTHCARE EXECUTIVE
Winner: Robert L. Meyer, Phoenix Children’s Hospital
Meyer is credited for the rapid and significant turnaround of Phoenix Children’s Hospital from the edge of financial failure to a successful $588 million expansion that made the hospital into one of the largest pediatric medical centers in the country. PCH is ranked in U.S. News & World Report’s Best Children’s Hospitals.

Finalists:
Tim Bricker, Chandler Regional and Mercy Gilbert
Mary Lee DeCoster, Maricopa Integrated Health System
Tony Marinello, CEO of Mountain Vista, IASIS Healthcare
Ed Myers, St. Luke’s Medical Center, IASIS Healthcare

HEALTHCARE ADVOCATE
Winner: Dr. John Chen, Maricopa Integrated Health System
Serving the community’s most vulnerable residents, Chen has helped thousands of patients within the Maricopa Integrated Health System. He sees patients who are in urgent need of treatment because of their lack of dental insurance or location in third world countries. He promotes dental care and hygiene to help prevent serious diseases.

Finalists:
Dr. Randal Christensen, Crews ‘n’ Healthcare
Gerri Hether, Orchard Medical Consulting

INSURANCE PROVIDER
Winner: Blue Cross Blue Shield of Arizona
Marking its 75th anniversary in Arizona, BCBSAZ is committed to improving the quality of life for all Arizonans. The company focuses on providing the best value in health insurance as well as outside programs targeted to children and their families to help reduce childhood obesity.

Finalists:
Health Net of Arizona
UnitedHealthcare of Arizona

LEGAL ADVOCATE
Winner: Kristen Rosati, Polsinelli
As an attorney dedicated to the healthcare industry, especially to healthcare privacy, health information exchange and clinical research, Rosati has written 12 books, 30 articles and made 200 presentations on healthcare topics. She also helped establish two nonprofits in Arizona that support health information exchange and health information technology.

Finalists:
Richard Mallery, Snell and Wilmer
Martin L. Shultz, Brownstein Hyatt Farber Schreck

MEDICAL CENTER OR HOSPITAL
Winner: Scottsdale Healthcare
As a nonprofit, Scottsdale Healthcare not only employs 6,500 staff members, but also is comprised of 1,400 volunteers who donate more than 155,000 hours of service each year. They are the largest employer in the City of Scottsdale and is known for its innovative medical technology, research and patient care.

Finalists:
Banner Good Samaritan Medical Center
Cancer Treatment Centers of America
St. Joseph’s Medical Center
St. Luke’s Medical Center

MEDICAL COMPANY OF THE YEAR
Winner: Ventana
Ventana is driving personalized healthcare through the development of “companion diagnostics” to identify patients most likely to respond favorably to specific therapies. Ventana has worked is currently engaged in more that 150 collaborative projects to develop and commercialize companion diagnostics globally.

Finalists:
Medtronic
W.L. Gore and Associates

MEDICAL RESEARCH COMPANY
Winner: Banner Alzheimer’s Institute
BAI has undergone a major prevention trial to evaluate a treatment in cognitively healthy older adults at the highest known genetic risk for developing Alzheimer’s disease at older ages. The study is part of the Alzheimer’s Prevention Initiative API, an international collaboration led by BAI to accelerate the evaluation of promising but unproven prevention therapies.

Finalists:
Banner MD Anderson
University of Arizona Cancer Center

PHYSICIAN OF THE YEAR
Winner: Jimmy Chow, IASIS Healthcare
Chow improved the field of orthopedics by helping to design and teach a hybrid technique of a minimally invasive total hip replacement where the surgeon builds a new hip from inside the body. This surgery results in no post-operative limitations and many patients are discharged within 24 hours. Chow is one of 10 surgeons in the world to perform his surgery.

Finalists:
Karen Corallo Chaney, Magellan Health Services
David Notrica, Phoenix Children’s Hospital

RESEARCHER OF THE YEAR
Winner: Venkatesh G. Ramaiah, Arizona Heart Hospital
Ramaiah, the medical director and director of vascular and endovascular research, successfully created the “un balloon,” which is used to remodel thoracic endografts without the wind sock effect. This products was able to be marketed and sold.

Finalists:
David Jacofsky, CORE Institute
Glen Weiss, CTCA

LIFETIME ACHIEVEMENT
Linda Hunt, Dignity Health
Hunt, who has served as the leader of Dignity Health in Arizona since 2012, has taken a leadership role to advance healthcare and the biosciences for the people of Arizona. She has worked diligently with legislators, business leaders, educators, scientists and community organizations in order to identify, formulate, and support policies that will give Arizonans better healthcare and raise the bar of knowledge.


Click here to see all the photos.

cancer

TGen finds clue to stop spread of lung cancer

Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute (TGen).

The hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14) are proteins associated with the potential spread of non-small cell lung cancer (NSCLC), according to the TGen study published online April 8 by the scientific journal Clinical & Experimental Metastasis.

NSCLC represents more than 85 percent of all lung cancers, which this year will kill an estimated 159,000 Americans, making it by far the leading cause of cancer-related death. It has a 5-year survival rate less than 10 percent.

The invasive and metastatic nature of NSCLC contributes to this high mortality rate, and so finding the cause of this potential to spread is key to helping patients survive.

Therapies targeting MET and FN14 are in clinical development, which could lead to treatments that could help halt or slow the spread of this lung cancer.

“As the metastatic phenotype is a major cause of lung cancer mortality, understanding and potentially targeting these pathways may reduce the high mortality rate in advanced lung cancer,” said Dr. Timothy Whitsett, an Assistant Professor in TGen’s Cancer and Cell Biology Division, and the study’s lead author.

Significantly, the TGen study found that MET and FN14 were elevated in metastatic tumors compared to primary lung tumors and suppression of MET activation or FN14 expression reduced tumor cell invasion.

“The elevation of these receptors in metastatic disease opens the possibility for therapeutic intervention,” said Dr. Nhan Tran, an Associate Professor in TGen’s Cancer and Cell Biology Division, and the study’s senior author.

Dr. Glen Weiss, Co-Unit Head of TGen’s Lung Cancer Research Laboratory and Director of Clinical Research at Cancer Treatment Centers of America at Western Regional Medical Center, said, “This study identifies some targets that already have drugs in clinical trials, and helps put them into context for what might be a rational drug development approach for the treatment of this deadly cancer.”

Other institutes that assisted with this study are: the University of Arizona; St. Joseph’s Hospital and Medical Center; and Humboldt Medical Specialists.

The study, FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion, was funded by the National Institutes of Health, and grants from the St. Joseph’s Foundation and the American Lung Association.